Table 1 Baseline characteristics of the 361 patients

Age (y)

49 (37, 59)^a

Gender (M/F), n (%)

195 (54 %)/166 (46 %)^b

Alcohol consumption, n (%)

33 (9.14 %)^b

Pre-existing liver disease, n (%)

91 (25.21 %)^b

HBV, n (%)

32 (8.86 %)^b

Autoimmune antibodies, n (%)

24 (6.65 %)^b

Alcoholic liver disease, n (%)

22 (6.09 %)^b

NAFLD, n (%)

13 (3.60 %)^b

Days from drug use to symptom appearance

30 (9, 60)^a

Days from drug discontinuation to symptom

 Disappearance

20 (12, 30)^a

 ALT (U/L)

225.7 (89.7, 541.3)^a

 AST (U/L)

125.8 (57.1, 325.1)^a

 ALP (U/L)

135.1 (81.7, 203.9)^a

 TBIL (μmol/L)

53 (14.5, 237.1)^a

 DBIL (μmol/L)

38.1 (6.7, 182.9)^a

 PT (s)

13.3 (12, 16.6)^a

 INR

1 (1, 1.4)^a

 TP (g/L)

53 (14.5, 237.1)^a

 ALB (g/L)

33.4 (29.5, 36.8)^a

 Cr (μmol/L)

56.1 (45.8, 69)^a

 MELD

6.9 (0.1, 13.3)^a

Type of DILI

 Hepatocellular, n (%)

228 (63.16 %)^b

 Cholestatic, n (%)

50 (13.85 %)^b

 Mixed, n (%)

48 (13.30 %)^b

 NA, n (%)

35 (9.70 %)^b